Rani Therapeutics (RANI) CEO purchases 35,000 shares in open-market trade

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. director and Chief Executive Officer Imran Talat purchased 35,000 shares of Class A Common Stock on July 17, 2026 at $0.7198 per share in an open-market transaction, bringing his direct holdings to 469,736 shares. This total includes 12,343 shares held by VH Moll, L.P., for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The Rule 10b5-1 trading-plan checkbox is unchecked.

Insider Trade Summary

Net Buyer: 35,000 shares

Net Buy 1 txn

Insider Imran Talat

Role Chief Executive Officer

Bought 35,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock F1	35,000	$0.7198	$25K

Holdings After Transaction: Class A Common Stock — 469,736 shares (Direct)

Footnotes (1)

1. F1. Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Key Figures

Shares purchased: 35,000 shares Purchase price: $0.7198 per share Shares held after transaction: 469,736 shares +1 more

4 metrics

Shares purchased 35,000 shares Class A Common Stock bought on July 17, 2026

Purchase price $0.7198 per share Average price for the 35,000 Class A shares

Shares held after transaction 469,736 shares Direct Class A holdings by CEO after the purchase

Shares held via VH Moll, L.P. 12,343 shares Included in the CEO’s reported post-transaction holdings

Key Terms

Class A Common Stock, beneficial ownership, pecuniary interest, Rule 10b5-1

4 terms

Class A Common Stock financial

"The reported transaction involves Class A Common Stock."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

beneficial ownership financial

"The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"Disclaims beneficial ownership except to the extent of his pecuniary interest therein."

Rule 10b5-1 financial

"The Rule 10b5-1 trading-plan checkbox is not selected for this transaction."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/21/2026 - 06:29 PM Accepted by SEC EDGAR 07/21/2026 - 06:29 PM Learn about SEC filing dates

FAQ

What insider share purchase did Rani Therapeutics (RANI) disclose for its CEO?

Rani Therapeutics reported that CEO Imran Talat purchased 35,000 Class A shares on July 17, 2026 at $0.7198 per share. After this open-market transaction, his direct holdings increased to 469,736 shares of Rani Therapeutics Class A Common Stock.

How many Rani Therapeutics (RANI) shares does CEO Imran Talat hold after the reported trade?

Following the July 17, 2026 purchase, Imran Talat directly holds 469,736 Class A shares. This figure includes 12,343 shares held by VH Moll, L.P., for which he disclaims beneficial ownership except to the extent of his pecuniary interest.

At what price did the Rani Therapeutics (RANI) CEO buy the 35,000 shares?

Imran Talat bought 35,000 Class A shares of Rani Therapeutics at an average price of $0.7198 per share. The transaction was reported as a purchase in an open-market or private transaction on July 17, 2026, increasing his overall share position.

Were the CEO’s Rani Therapeutics (RANI) share purchases made under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not selected, so the reported purchase was not affirmed as being made under a Rule 10b5-1 trading plan. It is reported simply as an open-market or private transaction by the CEO.

What portion of Rani Therapeutics (RANI) CEO Imran Talat’s holdings are held through VH Moll, L.P.?

Of the CEO’s reported 469,736 Class A shares, the total includes 12,343 shares held by VH Moll, L.P.. He disclaims beneficial ownership of those partnership-held shares except to the extent of his pecuniary interest in that entity.

Is the reported Rani Therapeutics (RANI) CEO transaction classified as a buy or sell?

The Form 4 classifies the July 17, 2026 transaction as a purchase of 35,000 Class A shares. The SEC coding and summary show it as a net buy, with no corresponding sales or derivative exercises reported in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imran Talat

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/17/2026		P		35,000	A	$0.7198	469,736(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

	/s/ Talat Imran	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)